Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aurobindo Says Nothing ‘Extraneous’ Holding Up FTC Nod For Sandoz Deal

Executive Summary

Aurobindo believes it has “substantially addressed” all requirements for an FTC go-ahead for its acquisition of Sandoz’s US dermatology and generic oral solids businesses. The integration of the acquired Apotex business in Europe is also shaping up.

You may also be interested in...



Aurobindo Hits Back Over Sandoz Delay Rumors

Aurobindo has hit back over rumors that completion of its pending transaction to acquire Sandoz’ US dermatology and oral-solids businesses has been delayed until next year over FTC information requests.

Aurobindo Faulted In US FDA Warning Letter For Poor Root Cause Investigations

Aurobindo failed to properly investigate problems with carcinogenic impurities in active pharmaceutical ingredients, warning letter says.

Big Statement By Aurobindo As It Seals $1bn Sandoz US Deal

Aurobindo is betting big, buying certain portions of Sandoz’s US portfolio in a deal potentially worth $1bn. The acquisition positions the Indian firm in the top league in the overall US generics space by Rx and also segments like dermatology, but much could depend on how effectively Aurobindo delivers on value creation potential amid ongoing price pressures.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM000882

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel